MK-2870-015
A Study to Evaluate Sacituzumab Tirumotecan in Advanced/Metastatic Gastroesophageal Adenocarcinoma
Active, Not Recruiting
Trial purpose
This study will compare how safe and effective sacituzumab tirumotecan is versus the treatment of physician’s choice (TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumab tirumotecan is superior to TPC with respect to Overall Survival (OS).
View full trial information on Clinicaltrials.govNATIONAL TRIAL REFERENCE NUMBER
NCT06356311
When you talk with your doctor or clinical trial team member, please have the national trial reference number available.
Eligibility
Only a qualified healthcare professional can determine if you are eligible to take part in a clinical trial. However, this information may be useful in starting a conversation with your doctor.
Conditions
Gastroesophageal Cancer
Age Range
18+
Sex
Male/Female
Study Details
Current trial Phase
Phase 3
Tests the medicine or vaccine in approximately 1,000 to 5,000 participants. For medicines, participants have the disease or condition the medicine is designed to treat. In vaccine trials, the participants may be healthy or have diseases or conditions. Phase 3 trials may happen in a doctor’s office, a clinic, or a hospital.
Trial start and end dates
- Trial start date 05-03-2024
- Estimated primary completion date 01-04-2027
- Estimated trial completion date 05-06-2027
Trial Locations
Locations shown may have changed in some cases. Please call the number listed in the location results to confirm the nearest trial site. Talk with a trial site member for more information.
Sorry, there are no locations found.